Parkin RBR E3 ubiquitin protein ligase (Parkin)

Parkin RBR E3 ubiquitin protein ligase is an enzyme encoded by the PRKN gene and functions as part of the E3 ubiquitin ligase family, specifically within the RBR (RING-between-RING) subtype. It catalyzes ubiquitination of a broad array of cytosolic and mitochondrial proteins, tagging them for degradation and playing a critical role in cellular protein clearance and mitochondrial quality control.[1][2][3][4][5][6] Under cellular stress, such as mitochondrial damage, Parkin is recruited and activated downstream of PINK1 kinase to initiate mitophagy. Parkin also protects neurons from oxidative stress-induced death, implicating it in neurodegenerative disease, especially Parkinson’s disease caused by PRKN mutations.[6][7][8] Its activity, structure, and regulatory mechanisms have been elucidated in atomic detail, highlighting its multi-domain organization and sophisticated autoinhibition and activation processes.[2][3][5] Parkin’s dysfunction, whether through genetic mutations or regulatory failures, is directly linked with juvenile Parkinson’s disease and may also play roles in cancer and inflammation. Although there are no drugs that directly modulate Parkin in clinical practice, its pathway is a major focus for neuroprotective drug development and therapy research.

Other names

ParkinPRKNPARK2E3 ubiquitin-protein ligase parkin

Experimental drugs may act by activating Parkin’s E3 ligase activity or modulating upstream regulators (e.g., PINK1 kinase activates Parkin by phosphorylation). Some research molecules aim to correct misfolded or mutated Parkin, restore ubiquitin ligase function, or enhance mitophagy.